IOVA vs. SWTX, DNLI, IMCR, TWST, ACLX, VCEL, RXRX, APGE, KYMR, and ADMA
Should you be buying Iovance Biotherapeutics stock or one of its competitors? The main competitors of Iovance Biotherapeutics include SpringWorks Therapeutics (SWTX), Denali Therapeutics (DNLI), Immunocore (IMCR), Twist Bioscience (TWST), Arcellx (ACLX), Vericel (VCEL), Recursion Pharmaceuticals (RXRX), Apogee Therapeutics (APGE), Kymera Therapeutics (KYMR), and ADMA Biologics (ADMA). These companies are all part of the "biological products, except diagnostic" industry.
Iovance Biotherapeutics (NASDAQ:IOVA) and SpringWorks Therapeutics (NASDAQ:SWTX) are both mid-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, community ranking, analyst recommendations, earnings, media sentiment, risk, institutional ownership, valuation and profitability.
SpringWorks Therapeutics has a net margin of 0.00% compared to Iovance Biotherapeutics' net margin of -23,615.70%. SpringWorks Therapeutics' return on equity of -66.48% beat Iovance Biotherapeutics' return on equity.
Iovance Biotherapeutics currently has a consensus price target of $24.64, indicating a potential upside of 140.59%. SpringWorks Therapeutics has a consensus price target of $68.83, indicating a potential upside of 53.51%. Given Iovance Biotherapeutics' higher possible upside, equities research analysts plainly believe Iovance Biotherapeutics is more favorable than SpringWorks Therapeutics.
77.0% of Iovance Biotherapeutics shares are owned by institutional investors. 10.4% of Iovance Biotherapeutics shares are owned by company insiders. Comparatively, 7.6% of SpringWorks Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Iovance Biotherapeutics has a beta of 0.66, suggesting that its share price is 34% less volatile than the S&P 500. Comparatively, SpringWorks Therapeutics has a beta of 0.84, suggesting that its share price is 16% less volatile than the S&P 500.
SpringWorks Therapeutics has higher revenue and earnings than Iovance Biotherapeutics. SpringWorks Therapeutics is trading at a lower price-to-earnings ratio than Iovance Biotherapeutics, indicating that it is currently the more affordable of the two stocks.
Iovance Biotherapeutics received 468 more outperform votes than SpringWorks Therapeutics when rated by MarketBeat users. Likewise, 74.50% of users gave Iovance Biotherapeutics an outperform vote while only 68.18% of users gave SpringWorks Therapeutics an outperform vote.
In the previous week, Iovance Biotherapeutics had 2 more articles in the media than SpringWorks Therapeutics. MarketBeat recorded 6 mentions for Iovance Biotherapeutics and 4 mentions for SpringWorks Therapeutics. SpringWorks Therapeutics' average media sentiment score of 0.90 beat Iovance Biotherapeutics' score of 0.67 indicating that SpringWorks Therapeutics is being referred to more favorably in the news media.
Summary
Iovance Biotherapeutics beats SpringWorks Therapeutics on 11 of the 17 factors compared between the two stocks.
Get Iovance Biotherapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for IOVA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IOVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Iovance Biotherapeutics Competitors List
Related Companies and Tools
